Trial Profile
A Phase 1 Trial of MLN0128 (TAK-228) in Combination With Osimertinib (AZD9291) in Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary) ; Sapanisertib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 21 Nov 2023 Planned End Date changed from 31 Aug 2023 to 29 Jun 2024.
- 21 Nov 2023 Planned primary completion date changed from 31 Aug 2023 to 29 Jun 2024.
- 15 Jul 2022 Planned End Date changed from 31 Aug 2022 to 31 Aug 2023.